Top Markets
Coin of the day
CARsgen Therapeutics Holdings Limited CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics Holdings Limited

2171
Rang in aandelen #9600
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in... CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
Aandeelprijs
$1.72
Laatst gesynchroniseerd: 2026-08-28
Marktkapitalisatie
$981.92M
Verandering (1 dag)
-1.68%
Verandering (1 jaar)
-41.83%
Land
CN
Handel CARsgen Therapeutics Holdings Limited (2171)

Categorie

P/S-ratio voor CARsgen Therapeutics Holdings Limited (2171)
P/S-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van CARsgen Therapeutics Holdings Limited is de huidige P/S-ratio (TTM) 0. Eind 2026 had het bedrijf een P/S-ratio van 0.
P/S-ratiohistoriek voor CARsgen Therapeutics Holdings Limited van 2026 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH